No connection

Search Results

BLCO vs MIRM

BLCO
Bausch + Lomb Corporation
BEARISH
Price
$16.98
Market Cap
$6.01B
Sector
Healthcare
AI Confidence
85%
MIRM
Mirum Pharmaceuticals, Inc.
BEARISH
Price
$96.49
Market Cap
$5.82B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BLCO
--
MIRM
--
Forward P/E
BLCO
21.5
MIRM
-888.74
P/B Ratio
BLCO
0.94
MIRM
15.91
P/S Ratio
BLCO
1.21
MIRM
11.17
EV/EBITDA
BLCO
19.71
MIRM
2731.73

Profitability

Gross Margin
BLCO
59.45%
MIRM
80.77%
Operating Margin
BLCO
6.25%
MIRM
-3.07%
Profit Margin
BLCO
-6.13%
MIRM
-4.48%
ROE
BLCO
-4.5%
MIRM
-8.65%
ROA
BLCO
0.53%
MIRM
-1.83%

Growth

Revenue Growth
BLCO
7.1%
MIRM
49.8%
Earnings Growth
BLCO
--
MIRM
--

Financial Health

Debt/Equity
BLCO
0.76
MIRM
1.02
Current Ratio
BLCO
1.51
MIRM
2.67
Quick Ratio
BLCO
0.74
MIRM
2.46

Dividends

Dividend Yield
BLCO
--
MIRM
--
Payout Ratio
BLCO
0.0%
MIRM
0.0%

AI Verdict

BLCO BEARISH

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak operational and balance sheet performance. Despite a reasonable Price/Book of 0.94 and a Debt/Equity ratio of 0.76, the company is unprofitable with a negative ROE of -4.50% and a profit margin of -6.13%. Earnings have collapsed year-over-year (-147.1%) and the last four quarters missed estimates by an average of -154.31%, signaling deteriorating fundamentals. While revenue growth of 7.10% and a gross margin above 59% provide some operational strength, the persistent earnings deterioration and lack of profitability undermine valuation support.

Strengths
Revenue growth of 7.10% YoY indicates top-line resilience in the medical instruments sector
Strong gross margin of 59.45% reflects pricing power and cost control in core operations
Debt/Equity ratio of 0.76 is below sector average of 2.69, suggesting conservative leverage
Risks
Piotroski F-Score of 2/9 signals severe financial distress and weak profitability trends
Negative ROE (-4.50%) and negative profit margin (-6.13%) indicate ongoing unprofitability
Earnings have collapsed with YoY EPS growth of -147.1% and Q/Q decline of -214.3%
MIRM BEARISH

MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.

Strengths
Strong YoY revenue growth of 49.80%
Excellent gross margins at 80.77%
Healthy short-term liquidity with a current ratio of 2.67
Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health
Aggressive insider selling across C-suite executives (CEO, CFO, President)
Extreme valuation multiples (Price/Book: 15.91, Price/Sales: 11.17)

Compare Another Pair

BLCO vs MIRM: Head-to-Head Comparison

This page compares Bausch + Lomb Corporation (BLCO) and Mirum Pharmaceuticals, Inc. (MIRM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile